TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04735822
Drug: Part 2: Belumosudil 200 mg Sequence HGI
DrugBank: Belumosudil (DB16703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen G (tablet), then Regimen I (oral suspension; subject fed)
Study: NCT00670501
Drug: teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 40 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
Study: NCT00670501
Drug: teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
Study: NCT04678856
Drug: Dupilumab SAR231893
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study: NCT00670501
Drug: Vitamin D Supplement
Normalized name: Vitamin D supplement
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement
Study: NCT01345136
Drug: RAD001, everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily
Study: NCT04548583
Drug: Remestemcel-L
Normalized name: remestemcel-L
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis
Study: NCT01488279
Drug: Dexamethasone 2.5 mg and Sitagliptin 100 mg
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received Dexamethasone 2.5mg plus Sitaliptin 100mg daily for 8 days
Study: NCT01488279
Drug: Dexamethasone 2.5 mg and placebo tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants rececived Dexamethasone 2.5 mg plus placebo tablet daily for 8 days
Study: NCT00990613
Drug: Dimebon Transdermal
Normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose in Cohort 1. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
Study: NCT02236403
Drug: Ivermectin 0.1% Metronidazole 1%
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05720572
Drug: Antazoline
Normalized name: Antazoline
DrugBank: Antazoline (DB08799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants assigned to the antazoline group will be administered antazoline in boluses in boluses of 100 mg diluted to 20 cm3 every 10 minutes up to a total dose of 300 mg diluted to 60 cm3 or conversion of AF to SR. Drug administration will also be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
Study: NCT05720572
Drug: Propafenone
Normalized name: Propafenone
DrugBank: Propafenone (DB01182)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients assigned to the propafenone group were administered three 20-cm3 boluses every 10 minutes up to 60 cm3 or conversion of AF to SR. Each of the first two boluses included 70 mg propafenone (total dose 140 mg), and the third bolus contained only 20-cm3 0.9% NaCl. Drug administration will be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
Study: NCT02651662
Drug: cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administration via intravenous (IV) infusion. The dose(s) received will be according to dose level (DL) cohort assignment, as described in the protocol.
Study: NCT04978025
Drug: Colloidal Silver
Normalized name: COLLOIDAL SILVER
DrugBank: Silver (DB12965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally: colloidal silver 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)~and By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days.
Study: NCT02651662
Drug: odronextamab
Normalized name: Odronextamab
DrugBank: Odronextamab (DB16684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration IV infusion. The dose(s) received will be according to DL cohort assignment, as described in the protocol.
Study: NCT00624481
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20ug subcutaneous injection daily for 24 weeks
Study: NCT00624481
Drug: Teriparatide Nasal Spray
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: teriparatide intranasally daily for 24 weeks
Study: NCT02421471
Drug: Ingenol mebutate 0.015 percent or 0.05 percent gel
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical treatment with ingenol mebutate gel 0.015 percent or 0.05 percent gel of skin areas affected by AK
Study: NCT03113071
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine will be administered in combination with Digoxin
Study: NCT03113071
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine will be administered in combination with Digoxin
Study: NCT01602120
Drug: Lampalizumab
Normalized name: Lampalizumab
DrugBank: Lampalizumab (DB11826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lampalizumab 10 mg ITV injections as per the schedule specified in respective arms.
Study: NCT03822468
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ribociclib (at a dosage of 400 mg or 600 mg) QD orally taken on days 1 to 21 of a 28-day cycle, followed by 7 days off ribociclib (days 22 to 28). Ribociclib is supplied as 200 mg tablets as individual patient supply packaged bottles.
Study: NCT03822468
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole 1 mg tablets for oral use QD continuously
Study: NCT05736081
Drug: Intravitreal dexamethasone implant
Normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravitreal implant of dexamethasone 0.7 mg with previous topic anesthesia and iodine drops
Study: NCT00567372
Drug: bevacizumab (Sub-tenon´s injection)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)
Study: NCT02866916
Drug: SXL01
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment will be administered continuously over 24h through the subcutaneous route.
Study: NCT01784445
Drug: Ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure
Study: NCT00863525
Drug: odanacatib
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 100 mg odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
Study: NCT00182091
Drug: Recombinant human growth hormone
Normalized name: Recombinant human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose based on age, sex, and estrogen status and ranged from 3-6 mcg/kg/day. GH doses were adjusted based on IGF-1 levels to target the mid-normal range for age.
Study: NCT00182091
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To maintain study-subject blinding, doses were sham adjusted.
Study: NCT00630565
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg/kg po in 4 divided doses (.8 mg/kg/dose orally every 6 hours) on days -7 through -4.
Study: NCT00630565
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg/m\^2 x 4 doses every 12 hours given intravenously (IV) push before cytoxan on day 0 and then every 12 hours
Study: NCT00630565
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2/day x 2 days (day 0-1) over 3 hours intravenously (IV)
Study: NCT00768183
Drug: KADIAN Capsule + water (under fasting conditions)
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules 100mg + 240 mL in 4 shots of 60 mL
Study: NCT00768183
Drug: morphine sulfate IR oral solution + water
Normalized name: morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate IR oral solution + water (under fasting conditions)
Study: NCT03822468
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 2.5 mg tablets for oral use QD continuously
Study: NCT00028782
Drug: etanidazole
Normalized name: Etanidazole
DrugBank: Etanidazole (DB12736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01010373
Drug: AS101
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 mg/m2 AS101 will be given intravenously (IV) three times per week.
Study: NCT03822468
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin 3.6 mg subcutaneously once every 4 weeks (pre-menopausal women only)
Study: NCT01787331
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02686840
Drug: sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~* Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~* Paracetamol, eight hourly, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception
Study: NCT02686840
Drug: vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic
Study: NCT03304080
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg orally daily, day 1 to day 28
Study: NCT03304080
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose I: 100 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle (Phase 1 only) Dose II: 125 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle
Study: NCT03304080
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg IV initial loading dose, followed by 6 mg/kg IV every 21 days
Study: NCT00911547
Drug: montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg tablet taken once daily at bedtime for 16 weeks
Study: NCT00911547
Drug: beclomethasone
Normalized name: Beclomethasone
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ug inhaled, taken twice daily for 16 weeks
Study: NCT03304080
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 840 mg IV followed by a maintenance dose of 420 mg IV every 21 days
Study: NCT00310401
Drug: Albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nebulized q4h
Study: NCT00310401
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.0 cc diluted with saline in identical fashion to study drug and administered by nebulizer every 4 hours
Study: NCT00191269
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
Study: NCT00191269
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
Study: NCT03817502
Drug: Cariprazine
Normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cariprazine capsules, oral administration, once daily.
Study: NCT00004762
Drug: cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00625352
Drug: Gemcitabine, UFT
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1,250mg/m2 IV on D1 and D8 of every 3 weeks combined with UFT 400mg daily PO for 14 days every 3 weeks. Gemcitabine will be administered to patients a maximum of 4 cycles, and then discontinued. UFT will be continued until progression.
Study: NCT04170790
Drug: Saxagliptin 5mg
Normalized name: Saxagliptin 5mg Oral tablet
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saxagliptin 5mg oral tablet
Study: NCT02028819
Drug: Dolutegravir Sodium Monohydrate
Normalized name: Dolutegravir Sodium
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir taken 50mg orally twice daily
Study: NCT02028819
Drug: Ibalizumab
Normalized name: ibalizumab
DrugBank: Ibalizumab (DB12698)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ibalizumab will be administered intravenously at a dose of 800mg once every two weeks.
Study: NCT01590459
Drug: VX-509
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral tablet
Study: NCT01201785
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After having been on aspirin 81mg/daily for at least one-week, patients switched their aspirin regimen on a weekly basis according to the following scheme: aspirin 81mg twice daily (bid) for one week; aspirin 162 mg once daily (od) for one week; aspirin 162 mg bid for one week; aspirin 325 mg od for one week. Pharmacodynamic assessments were made after each sequence (5 time-points). Afterward, patients resumed the dose of aspirin that they were on prior to entering the study.
Study: NCT04170790
Drug: Sildenafil 50 mg
Normalized name: sildenafil 50 MG
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil 50 mg Oral Tablet
Study: NCT01195090
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: add sitagliptin100mg/d to pre-study OADs
Study: NCT01195090
Drug: pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: add pioglitazone 30mg/d to pre-study OADs
Study: NCT03945591
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.3 mg/m2 IV 6 hours after graft infusion and 72 hours thereafter.
Study: NCT00791258
Drug: amlodipine and olmesartan medoxomil tablets
Normalized name: Amlodipine and Olmesartan Medoxomil Tablets
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine and olmesartan medoxomil tablets administered orally, once daily for up to 20 weeks
Study: NCT00791258
Drug: hydrochlorothiazide tablets
Normalized name: Hydrochlorothiazide Tablets
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydrochlorothiazide tablets may be administered orally, if necessary once daily, for up to 8 weeks
Study: NCT03703167
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral ibrutinib will be given between days 1 and 28 of each 28-day cycle and will be continued daily after completion of rituximab and lenalidomide. The starting dose of ibrutinib is 560 mg/day (dose level 1) and (dose level 2 ibrutinib: 840 mg daily).
Study: NCT03703167
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral lenalidomide will be given between days 1 and 21 of each 28-day cycle for a maximum of 12 cycles. The starting dose of lenalidomide is 10 mg/day (dose level 1 \& 2) lenalidomide: 15 mg daily (dose level 3) and lenalidomide: 20 mg daily (dose level 4).
Study: NCT03703167
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous rituximab (500mg/m2) will be given on day 1 of all cycles (+/- 3 days), for up to 6 cycles.
Study: NCT00544050
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03083847
Drug: Chloroquine Phosphate
Normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine has been widely used for treatment and prophylaxis of malaria since 1946 (Most, London et al. 1984). It was the treatment of choice for uncomplicated malaria for decades because it was safe, well tolerated, affordable and highly effective for the treatment of malaria. However, increasing spread of chloroquine- resistant Pf over the last two decades has severely limited its use (Wellems 2002). Chloroquine phosphate is U.S Food and Drug Administration (FDA) approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf.
Study: NCT04600141
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab infusion 8mg/kg/dose - Intravenous single dose.
Study: NCT03083847
Drug: Pyrimethamine
Normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrimethamine is a folic acid antagonist that has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide (Organization April 2013 (rev. January2014)
Study: NCT00955812
Drug: OPB-31121
Normalized name: OPB-111077
DrugBank: OPB-111077 (DB16630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
Study: NCT02426944
Drug: NOAC
Normalized name: Aminoacylase
DrugBank: 5-Bromo-N[2-(Dimethylamino)Ethyl]-9-Aminoacridine-4-Carboxamide (DB02390)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical arm, patients will be treated by NOAC.
Study: NCT04209192
Drug: Fosfomycin Tromethamine 3G Sachet
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Is the prophylactic drug which will be used in the intervention group.
Study: NCT01200004
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle.
Study: NCT01200004
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
Study: NCT01200004
Drug: Grifola Frondosa
Normalized name: GRIFOLA FRONDOSA WHOLE
DrugBank: Grifola frondosa whole (DB19262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg by mouth twice a day on days 1 - 21 of a 28 day cycle.
Study: NCT01887951
Drug: Tramadol Injection
Normalized name: tramadol Injectable Solution
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006345
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02677948
Drug: Pacritinib
Normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02677948
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00868426
Drug: Budesonide/Formoterol Batch 1
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single, inhaled dose
Study: NCT00868426
Drug: Budesonide/Formoterol Batch 2
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single, inhaled dose
Study: NCT00868426
Drug: Budesonide/Formoterol Batch 1 and charcoal
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single, inhaled dose
Study: NCT01368536
Drug: Valturna
Normalized name: Valturna
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valturna (aliskiren 150 mg/valsartan 160 mg) tablet
Study: NCT01368536
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg and 10 mg capsule
Study: NCT01621230
Drug: Epidural Bupivacaine plus fentanyl
Normalized name: Fentanyl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The subjects will receive 0.125% bupivacaine with fentanyl 2 mcg/mL at a rate of 10 mL/hr.
Study: NCT04587011
Drug: Tegoprazan dose A or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan A mg or placebo taken orally twice daily for 3 days.